Home › Research › Topics › frontotemporal
frontotemporal
1,022 studies tagged frontotemporal, dated 1967-05-01 to 2026-09-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis 2026-09-22
- Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration 2026-09-21
- Diagnostic Value of Large Language Model-Extracted Gross Brain Findings in Neurodegenerative Diseases 2026-09-14
Studies
1,022 studies carry this tag.
Date range
1967 to 2026
Top journals
- Neurology 106
- Brain : a journal of neurology 71
- Movement disorders : official journal of the Movement Disorder Society 53
- Annals of neurology 34
- The Lancet. Neurology 34
313 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
53/100
In the Rush dataset, we included 1,277 women and 579 men.
-
44/100
The most common clinical symptoms in FTLD-TDP-PSP were memory loss (100%) followed by parkinsonism (80%), early falls (60%), and behavioral variant FTD (60%).
-
Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB.
-
NfL holds potential as a blood-based biomarker for symptomatic genetic FTD carriers, with moderate accuracy to distinguish PPD from mild forms including C9orf72 .
-
Median survival from symptom onset was longest in SD (11.9 years) and shortest in LPA (7 years).
-
Forty-nine outcomes were presented to survey respondents.
-
Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), is characterized by cognitive decline, sleep disturbances, motor dysfunction, and other debilitating clinical symptoms.
-
Dementia with Lewy bodies (DLB) is thought to be the second most common form of dementia after Alzheimer’s disease, and is characterised by a combination of cognitive, neuropsychiatric and motor symptoms.
-
Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society.
-
In plasma, most complement analytes were not significantly different between spFTD and HC; the exceptions were C4 and FB, significantly decreased in spFTD vs HC ( p = 0.0192 and p = 0.0181, respectively), suggesting complement consumption in classical and alternative pathways.
-
In contrast, patients with LB pathology alone, in the absence of AD biomarker positivity, had less overall cognitive impairment but more focal dysexecutive and visuospatial deficits.
-
Patients with DLB had significantly greater rates of hospitalization and ED visits compared to patients with AD (Incidence Rate Ratio (IRR): 1.46, 95% CI 1.24, 1.73, IRR: 1.46, 95% CI 1.29, 1.77, respectively) and controls (IRR: 1.77, 95% CI 1.46, 2.14, IRR: 2.21, 95% CI 1.82, 2.69, respectively) and ED visits compared to those with VD (IRR: 1.24, 95% CI 1.03, 1.50).
-
The identification of biomarkers predicting the burden of brain alpha-synuclein (α-syn) pathology in vivo represents a research priority in Lewy body disease (LBD).
-
The LBD-present group had higher QSM values in the SNc (P = 0.008) than the LBD-absent group with no differences in SNr.
-
26% of the participants experienced delirium prior to diagnosis of DLB, with one participant experiencing multiple episodes in the 24 months before diagnosis.
-
Surprisingly, levels of strain A and B aSyn species were higher in plasma from individuals with PD compared to DLB in 2 independent cohorts.
-
Of 43 individuals enrolled, 14 were women (33%); age (mean ± SD) was 73 ± 8.5 years.
-
Neighborhood deprivation is associated with shorter survival, cognitive impairment and neurodegeneration in aging and Alzheimer's disease.
-
The study cohort included 245 patients with FTD (121 female [49.4%], 124 male [50.6%]; mean [SD] age, 65.2 [8.7] years), 2416 matched HCs (1190 female [49.3%], 1226 male [50.7%]; mean [SD] age, 65.0 [8.5] years), and 1326 patients with AD (777 female [58.6%], 549 male [41.4%]; mean [SD] age, 71.7 [9.8] years).
-
Lewy body-involving diseases (LBD) are commonly associated with Parkinson's disease (PD) featuring voluntary movement inhibition, due to dopaminergic neuron dysfunction in the substantia nigra.
-
= 62.87, SD = 9.46, 36.52% female). Both networks were densely connected, reflecting comorbidity between neuropsychiatric symptoms and cognitive scores.
-
Levodopa/carbidopa is the cornerstone treatment for Parkinson's disease (PD), but in patients with dysphagia, there are limited options for the routes of administration.
-
87 DLB patients (77.5 ± 7.2yo; 34.5 % females) were included.
-
At the initial visit, the mean age of individuals with DLB was 80.8 (5.8) years; their mean Mini-Mental State Examination score was 20.6 (5.1).
-
Parkinson's disease (PD) exhibits a variety of symptoms, with approximately 25% of patients experiencing mild cognitive impairment and 45% developing dementia within ten years of diagnosis.
-
Dementia with Lewy bodies (DLB) frequently coexists with Alzheimer's disease pathology, yet the pattern of cortical microstructural injury and its relationship with amyloid, tau, and cerebrovascular pathologies remains unclear.
-
Individual cognitive profiles of patients with Parkinson's disease dementia (PDD) are highly heterogeneous, suggesting possible biological subtypes.
-
The aetiology of HS-A is heterogeneous, but HS-A is strongly associated with limbic-predominant age-related TDP-43 encephalopathy NC (LATE-NC).
-
Higher general burden was associated with female caregivers (β = −.19, p = .05), higher education (β = .16, p = .03), caring for someone with dementia (β = .36, p = .01), and greater dysphagia-related burden (β = .33, p = .01).
-
DLB patients had a higher prevalence of VH than AD patients (p < 0.01).
-
Lewy body diseases are common neurodegenerative diseases, including Parkinson's disease (PD) and dementia with Lewy bodies, which lead to both motor and non-motor symptoms.
-
47/100
We show reduced fiber cross-section in LBD versus PD, and increased concentrations of plasma neurofilament light chain and p-tau217; with p-tau217 and fiber cross-section associated with cognition.
-
< .01). All patient groups were also impaired on AVLT encoding, TMT-B and TMT B/A. Social and non-social neurocognitive functions differed between groups, with specific impairments in processing speed in VaD, emotion recognition in bv-FTD and memory retrieval in AD, and memory encoding and cognitive control impaired in all three groups.
-
Males were more likely than females to present with two or more core DLB clinical features 2 years prior to obtaining a diagnosis of dementia.
-
Early onset hallucinations were significantly more common in pLBD than pAD (OR 0.069 [95% CI 0.012-0.397], p = 0.003) or mixed AD+LBD (OR 0.09 [95% CI 0.010-0.771], p = 0.028) and there was a greater increase in the odds of hallucinations over time in pAD and AD+LBD than pLBD such that there was was no difference in the prevalence of late-onset hallucinations between pLBD, pAD or AD+LBD.
-
Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci identified.
-
To develop a simplified smell test for identifying patients with Parkinson's disease (PD), we reevaluated the Sniffin'-Sticks-Identification-Test (SST-ID) and University-of-Pennsylvania-Smell-Identification-Test (UPSIT), using three case-control studies.
-
Lewy body dementia (LBD) encompasses neurodegenerative dementias characterized by cognitive fluctuations, visual hallucinations, and parkinsonism.
-
• Patients with Parkinson's disease (PD) and cognitive impairment demonstrated a significantly greater burden of white matter hyperintensities (WMH), with the highest burden observed in those with PD dementia.
-
63/100
Common variants within TMEM106B are associated with risk for frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP).
-
The results showed that bilinguals had reduced thalamic volume compared to monolinguals despite having similar cognitive performance.
-
Of the 1388 studies identified, 70 met the inclusion criteria for this review.
-
Neuro Degenerative Disorders (NDDs) involve progressive nerve cell loss, impacting functions like sensation, movement, memory, and cognition, posing life-threatening risks.
-
44/100
Neuropsychiatric symptoms (NPS) are prevalent, emerge early, and are associated with poorer outcomes in Lewy body dementia (LBD).
-
Both LBDs and SPs exhibit distinct visual aberrations, ranging from minor metamorphopsias to complex hallucinations.
-
UNC13A (rs12608932-CC) is associated with both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and shortens survival in ALS.
-
Our case series highlighted the relevance of neurological comorbidities in BP patients; although the pathogenesis is still to be elucidated, the neuroinflammation present in neurodegenerative diseases could explain the neurocutaneous link and the chronological relationship between these entities.
-
42/100
Compared to controls, PSP and bvFTD had lower values of midbrain area, HBS-RS and GMA, and higher MRPI and MRPI 2.0.
-
Onset-predictive biomarker tests (OPBTs) for genetic frontotemporal dementia (FTD) may predict symptom onset in coming years.
-
Existing models of frontotemporal dementia (FTD) may not fully recapitulate the pathophysiology of the disease.
From across this tag
10 of the 1,021 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study
- Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium
- Key motor and non-motor features in early dementia with Lewy bodies
- Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated
- Olfactory bulb involvement in neurodegenerative diseases
- Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease
- Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review
- Fusing the Virtual and Physical Worlds to Identify Declines in Instrumental Activities of Daily Living Associated with Parkinson’s Disease (S37.008)
- Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis
- Lewy body disease or diseases with Lewy bodies?